Get the Stockscreener App
80.20
0.31%
-0.575
Insmed Inc stock is traded at $80.20, with a volume of 940.33K.
It is down -0.31% in the last 24 hours and up +21.81% over the past month.
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
See More
Previous Close:
$80.78
Open:
$81.33
24h Volume:
940.33K
Relative Volume:
0.55
Market Cap:
$14.45B
Revenue:
$342.96M
Net Income/Loss:
$-864.29M
P/E Ratio:
-14.45
EPS:
-5.55
Net Cash Flow:
$-636.03M
1W Performance:
+5.16%
1M Performance:
+21.81%
6M Performance:
+13.44%
1Y Performance:
+177.79%
1-Day Range:
$78.94
$81.33
1-Week Range:
$74.47
$82.04
52-Week Range:
$21.92
$82.04
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
80.25 | 14.45B | 342.96M | -864.29M | -636.03M | -5.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.86 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.92 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.86 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Morgan Stanley Raises Insmed (NASDAQ:INSM) Price Target to $90.00 - MarketBeat
Employee Stock Options Alert: Insmed Grants 77.88/Share to 66 New HiresStrategic Growth Move - StockTitan
Insmed Incorporated (NASDAQ:INSM) Shares Acquired by abrdn plc - MarketBeat
William Lewis Sells 18,750 Shares of Insmed Incorporated (NASDAQ:INSM) Stock - MarketBeat
Insmed CEO William Lewis sells $1.99 million in stock - MSN
SG Americas Securities LLC Reduces Stock Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
FDA Priority Review for Insmed's brensocatib for bronchiectasis - The Pharma Letter
Insmed Gets Speedy FDA Review of Brensocatib for Bronchiectasis -February 06, 2025 at 08:46 am EST - Marketscreener.com
Insmed’s Brensocatib NDA Accepted by FDA - TipRanks
Insmed Gets Speedy FDA Review of Brensocatib for Bronchiectasis - MarketWatch
Morgan Stanley Raises Price Target on Insmed to $90 From $85, Keeps Overweight Rating - Marketscreener.com
FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025 - PR Newswire
Insmed (NASDAQ:INSM) Hits New 1-Year HighHere's Why - MarketBeat
China Universal Asset Management Co. Ltd. Raises Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed CEO William Lewis sells $1.99 million in stock By Investing.com - Investing.com South Africa
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years - Benzinga
Insmed Incorporated (NASDAQ:INSM) Receives $83.67 Average Price Target from Brokerages - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Holdings Lifted by Blue Trust Inc. - Defense World
SG Americas Securities LLC Lowers Holdings in Insmed Incorporated (NASDAQ:INSM) - Defense World
Waldron Private Wealth LLC Acquires New Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Short Interest Update - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Insider Orlov S. Nicole Schaeffer Sells 91,140 Shares - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Jennison Associates LLC - MarketBeat
Insmed (NASDAQ:INSM) Reaches New 52-Week HighHere's Why - MarketBeat
Top 10 Takeover Targets of 2025 - Genetic Engineering & Biotechnology News
Positive Outlook for Insmed with Promising TPIP Phase 2 Data and Potential Market Advancements - TipRanks
Insmed stock soars to 52-week high, hits $80.55 - MSN
35,478 Shares in Insmed Incorporated (NASDAQ:INSM) Purchased by Moody Aldrich Partners LLC - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Given Average Recommendation of “Buy” by Brokerages - Defense World
Insmed stock soars to 52-week high, hits $80.55 By Investing.com - Investing.com Canada
Nisa Investment Advisors LLC Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World
BEFORE THE BELL-Insmed shares down after Iplex move - Reuters
Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Park Avenue Securities LLC - Defense World
Truist maintains Buy on Insmed stock, price target steady at $105 - MSN
Brokers Set Expectations for Insmed FY2025 Earnings - Defense World
FY2026 EPS Estimates for Insmed Decreased by Leerink Partnrs - Defense World
Leerink Partnrs Has Weak Estimate for Insmed FY2026 Earnings - MarketBeat
Cantor Fitzgerald Weighs in on Insmed FY2025 Earnings - MarketBeat
Bronchiectasis Market to Show Positive Growth at a CAGR of 13.7% by 2034 | DelveInsight - GlobeNewswire Inc.
The five-year returns have been solid for Insmed (NASDAQ:INSM) shareholders despite underlying losses increasing - Yahoo Finance
Insmed CEO William Lewis sells shares worth $2.71 million - MSN
Insmed Incorporated (NASDAQ:INSM) Short Interest Up 18.7% in December - MarketBeat
Is Insmed (NASDAQ:INSM) Using Debt Sensibly? - Simply Wall St
Insmed chief medical officer sells $95,108 in stock - MSN
Is Insmed Incorporated (INSM) One of the Best Russell 2000 Stocks to Invest in According to Analysts? - Yahoo Finance
Insmed (FRA:IM8N) Shares Outstanding (EOP) : 178.8 Mil (As of Sep. 2024) - GuruFocus.com
Insmed's chief people strategy officer sells $59,923 in stock - MSN
Goldman Sachs Sees High Merger Odds For This Large-Cap Biopharma In Trump 2.0 Era: Retail Has Been Alert - MSN
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):